

cecava is a biopharmaceutical immuno-oncology company pioneering the development of personalized neoepitope-based cancer vaccines. For cecava's therapeutic approach, the clinically most relevant neoepitopes are derived from patient-individual tumor mutations using the company's proprietary in silico pipeline. The neoepitope peptides are synthesized, formulated into vaccines and injected into the skin of the respective patient. Through the vaccination, the power of the patient's immune system is unleashed to recognize and destroy tumor cells presenting the neoepitopes on their surface. The Tübingen-based company currently prepares first clinical trials for several tumor indications to obtain marketing authorization for the innovative treatment concept.